Teruo Kitagawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Teruo Kitagawa has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Akemi Tanaka
Osaka City University Graduate School of Medicine
2 shared publicationsKen Suzuki
Tokyo Health Service Association
2 shared publicationsMasahisa Kobayashi
Tokyo Jikei University School of Medicine
2 shared publicationsMisao Owada
Kagawa Nutrition University, Graduate School
2 shared publicationsNobuyuki Ishige
Tokyo Health Service Association
2 shared publicationsToya Ohashi
Tokyo Jikei University School of Medicine
2 shared publications
Latest Publications
- Open Access
- 15 December 2015
- Published by Springer Nature in BMC Pediatrics
- Vol. 15 (1) , 1-8
Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study
Congenital adrenal hyperplasia (CAH) cause life-threatening adrenal crisis. It also affects fetal sex development and can result in incorrect sex assignment at birth. In 1989, a newborn screening program for congenital adrenal hyperplasia (CAH) was introduced in Tokyo. Here we present the results of this screening program in order to clarify the efficiency of CAH screening and the incidence of CAH in Japan. From 1989 to 2013, a total of 2,105,108 infants were screened for CAH. The cutoff level for diagnosis of CAH was adjusted for gestational age and birth weight. A total of 410 infants were judged positive, and of these, 106 patients were diagnosed with CAH, indicating a positive predictive value (PPV) of 25.8 %. Of the 106 patients, 94 (88.7 %) were diagnosed with 21-OHD. Of these 94 patients, 73 were diagnosed with the salt wasting form, 14 with the simple virilising form and 7 with the nonclassical form (NC21OHD). The mean birth weight and gestational age were 3192 ± 385 g and 38.9 ± 1.38 weeks. 11 out of 44 female patients were assigned as female according to their screening result. These data suggest that the newborn screening in Tokyo was effective, especially for sex assignment and preventing fatal adrenal crisis. The incidence of CAH was similar to that measured in previous Japanese screening studies, and it was also similar to that of western countries. The incidence of NC21OHD in Japan in the present study was lower than that in western countries as previous studies reported. The screening program achieved higher PPV than previous CAH screening studies, which might be due to the use of variable cutoffs according to gestational age and birth weight. However, most of the neonates born at 37 weeks or less that were referred to hospital were false-positives. Further changes are needed to reduce the number of false positive preterm neonates.
- 15 December 2015
- Published by Springer Nature in BMC Pediatrics
- Vol. 15 (1) , 1-8
Open AccessNewborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study
Congenital adrenal hyperplasia (CAH) cause life-threatening adrenal crisis. It also affects fetal sex development and can result in incorrect sex assignment at birth. In 1989, a newborn screening program for congenital adrenal hyperplasia (CAH) was introduced in Tokyo. Here we present the results of this screening program in order to clarify the efficiency of CAH screening and the incidence of CAH in Japan. From 1989 to 2013, a total of 2,105,108 infants were screened for CAH. The cutoff level for diagnosis of CAH was adjusted for gestational age and birth weight. A total of 410 infants were judged positive, and of these, 106 patients were diagnosed with CAH, indicating a positive predictive value (PPV) of 25.8 %. Of the 106 patients, 94 (88.7 %) were diagnosed with 21-OHD. Of these 94 patients, 73 were diagnosed with the salt wasting form, 14 with the simple virilising form and 7 with the nonclassical form (NC21OHD). The mean birth weight and gestational age were 3192 ± 385 g and 38.9 ± 1.38 weeks. 11 out of 44 female patients were assigned as female according to their screening result. These data suggest that the newborn screening in Tokyo was effective, especially for sex assignment and preventing fatal adrenal crisis. The incidence of CAH was similar to that measured in previous Japanese screening studies, and it was also similar to that of western countries. The incidence of NC21OHD in Japan in the present study was lower than that in western countries as previous studies reported. The screening program achieved higher PPV than previous CAH screening studies, which might be due to the use of variable cutoffs according to gestational age and birth weight. However, most of the neonates born at 37 weeks or less that were referred to hospital were false-positives. Further changes are needed to reduce the number of false positive preterm neonates.
- 6 June 2008
- Published by Springer Nature in Pediatric Nephrology
- Vol. 23 (9) , 1461-1471
Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes
- 6 June 2008
- Published by Springer Nature in Pediatric Nephrology
- Vol. 23 (9) , 1461-1471
Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes
- 1 July 2005
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 85 (3) , 196-202
Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry
- 1 July 2005
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 85 (3) , 196-202
Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry